Efficacy and Posttreatment Effects of Therapist-Delivered Cognitive Behavioral Therapy vs Supportive Psychotherapy for Adults With Body Dysmorphic Disorder: A Randomized Clinical Trial.


Journal

JAMA psychiatry
ISSN: 2168-6238
Titre abrégé: JAMA Psychiatry
Pays: United States
ID NLM: 101589550

Informations de publication

Date de publication:
01 04 2019
Historique:
pubmed: 21 2 2019
medline: 15 2 2020
entrez: 21 2 2019
Statut: ppublish

Résumé

Cognitive behavioral therapy (CBT), the best-studied treatment for body dysmorphic disorder (BDD), has to date not been compared with therapist-delivered supportive psychotherapy, the most commonly received psychosocial treatment for BDD. To determine whether CBT for BDD (CBT-BDD) is superior to supportive psychotherapy in reducing BDD symptom severity and associated BDD-related insight, depressive symptoms, functional impairment, and quality of life, and whether these effects are durable. This randomized clinical trial conducted at Massachusetts General Hospital and Rhode Island Hospital recruited adults with BDD between October 24, 2011, and July 7, 2016. Participants (n = 120) were randomized to the CBT-BDD arm (n = 61) or the supportive psychotherapy arm (n = 59). Weekly treatments were administered at either hospital for 24 weeks, followed by 3- and 6-month follow-up assessments. Measures were administered by blinded independent raters. Intention-to-treat statistical analyses were performed from February 9, 2017, to September 22, 2018. Cognitive behavioral therapy for BDD, a modular skills-based treatment, addresses the unique symptoms of the disorder. Supportive psychotherapy is a nondirective therapy that emphasizes the therapeutic relationship and self-esteem; supportive psychotherapy was enhanced with BDD-specific psychoeducation and treatment rationale. The primary outcome was BDD symptom severity measured by the change in score on the Yale-Brown Obsessive-Compulsive Scale Modified for BDD from baseline to end of treatment. Secondary outcomes were the associated symptoms and these were assessed using the Brown Assessment of Beliefs Scale, Beck Depression Inventory-Second Edition, Sheehan Disability Scale, and Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form. Of the 120 participants, 92 (76.7%) were women, with a mean (SD) age of 34.0 (13.1) years. The difference in effectiveness between CBT-BDD and supportive psychotherapy was site specific: at 1 site, no difference was detected (estimated mean [SE] slopes, -18.6 [1.9] vs -16.7 [1.9]; P = .48; d growth-modeling analysis change, -0.25), whereas at the other site, CBT-BDD led to greater reductions in BDD symptom severity, compared with supportive psychotherapy (estimated mean [SE] slopes, -18.6 [2.2] vs -7.6 [2.0]; P < .001; d growth-modeling analysis change, -1.36). No posttreatment symptom changes were observed throughout the 6 -months of follow-up (all slope P ≥ .10). Body dysmorphic disorder severity and associated symptoms appeared to improve with both CBT-BDD and supportive psychotherapy, although CBT-BDD was associated with more consistent improvement in symptom severity and quality of life. ClinicalTrials.gov identifier: NCT01453439.

Identifiants

pubmed: 30785624
pii: 2725087
doi: 10.1001/jamapsychiatry.2018.4156
pmc: PMC6450292
doi:

Banques de données

ClinicalTrials.gov
['NCT01453439']

Types de publication

Comparative Study Journal Article Randomized Controlled Trial Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

363-373

Subventions

Organisme : NIMH NIH HHS
ID : R01 MH091023
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH091078
Pays : United States

Commentaires et corrections

Type : CommentIn
Type : ErratumIn

Références

J Anxiety Disord. 2013 Dec;27(8):772-80
pubmed: 23816349
Behav Ther. 2011 Dec;42(4):624-33
pubmed: 22035991
J Consult Clin Psychol. 1998 Oct;66(5):862-6
pubmed: 9803707
J Behav Ther Exp Psychiatry. 2012 Jun;43(2):724-9
pubmed: 22080870
World Psychiatry. 2015 Oct;14(3):270-7
pubmed: 26407772
Arch Gen Psychiatry. 2002 Apr;59(4):381-8
pubmed: 11926939
Psychiatry Res. 2010 Oct 30;179(3):318-23
pubmed: 20493560
Am J Psychiatry. 1998 Jan;155(1):102-8
pubmed: 9433346
J Int Neuropsychol Soc. 2000 Sep;6(6):673-81
pubmed: 11011514
Behav Res Ther. 1996 Sep;34(9):717-29
pubmed: 8936754
Arch Gen Psychiatry. 2007 Dec;64(12):1417-25
pubmed: 18056550
Psychother Psychosom. 2014;83(6):341-53
pubmed: 25323062
Psychother Psychosom. 2008;77(2):101-10
pubmed: 18230943
Am J Psychiatry. 1999 Nov;156(11):1780-6
pubmed: 10553743
J Behav Ther Exp Psychiatry. 1995 Jun;26(2):113-20
pubmed: 7593683
J Clin Psychiatry. 2016 Jul;77(7):927-35
pubmed: 27464313
BMJ. 2016 Feb 02;352:i241
pubmed: 26837684
Am J Psychiatry. 2006 Jul;163(7):1280-2
pubmed: 16816236
Psychopharmacol Bull. 1997;33(1):17-22
pubmed: 9133747
J Consult Clin Psychol. 1995 Apr;63(2):263-9
pubmed: 7751487
J Behav Ther Exp Psychiatry. 2000 Jun;31(2):73-86
pubmed: 11132119
Behav Ther. 2014 May;45(3):314-27
pubmed: 24680228
Contemp Clin Trials Commun. 2018 Mar 28;10:80-85
pubmed: 29696162
Clin Psychol Rev. 2016 Aug;48:43-51
pubmed: 27393916
J Psychiatr Res. 2008 Jul;42(9):701-7
pubmed: 18377935
Psychopharmacol Bull. 1993;29(2):321-6
pubmed: 8290681
Eval Program Plann. 1982;5(3):233-7
pubmed: 10259963
Psychother Psychosom. 2000 May-Jun;69(3):137-46
pubmed: 10773778
J Psychosom Res. 2015 Mar;78(3):223-7
pubmed: 25595027
Psychol Med. 2013 May;43(5):1109-17
pubmed: 23171833
CNS Spectr. 2008 Apr;13(4):316-22
pubmed: 18408651
Psychiatry Res. 2010 Jun 30;178(1):171-5
pubmed: 20452057
Psychol Med. 2006 Jun;36(6):877-85
pubmed: 16515733
Psychol Methods. 2009 Mar;14(1):43-53
pubmed: 19271847

Auteurs

Sabine Wilhelm (S)

Department of Psychiatry, Massachusetts General Hospital, Boston.
Department of Psychiatry, Harvard Medical School, Boston, Massachusetts.

Katharine A Phillips (KA)

Department of Psychiatry, Rhode Island Hospital, Providence.
Department of Psychiatry, New York-Presbyterian Hospital, New York.
Department of Psychiatry and Human Behavior, Alpert Medical School of Brown University, Providence, Rhode Island.
Department of Psychiatry, Weill Cornell Medical College, New York, New York.

Jennifer L Greenberg (JL)

Department of Psychiatry, Massachusetts General Hospital, Boston.
Department of Psychiatry, Harvard Medical School, Boston, Massachusetts.

Sheila M O'Keefe (SM)

Department of Psychiatry, Massachusetts General Hospital, Boston.
Department of Psychiatry, Harvard Medical School, Boston, Massachusetts.

Susanne S Hoeppner (SS)

Department of Psychiatry, Massachusetts General Hospital, Boston.
Department of Psychiatry, Harvard Medical School, Boston, Massachusetts.

Aparna Keshaviah (A)

Mathematica Policy Research, Cambridge, Massachusetts.

Suraj Sarvode-Mothi (S)

Department of Psychiatry, Massachusetts General Hospital, Boston.

David A Schoenfeld (DA)

Department of Psychiatry, Harvard Medical School, Boston, Massachusetts.
Department of Biostatistics, Massachusetts General Hospital, Boston.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH